JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maecke, H. R.
Right arrow Articles by Haberkorn, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maecke, H. R.
Right arrow Articles by Haberkorn, U.

68Ga-Labeled Peptides in Tumor Imaging

Helmut R. Maecke, PhD1, Michael Hofmann, MD2 and Uwe Haberkorn, MD3

1 Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Basel, Switzerland
2 Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
3 Department of Nuclear Medicine, University of Heidelberg and Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany



View larger version (13K):

[in a new window]
  		FIGURE 1. Structural formula of DOTATOC.

 


View larger version (14K):

[in a new window]
  		FIGURE 2. Structural formula of NODAGATOC.

 


View larger version (40K):

[in a new window]
  		FIGURE 3. Coronal images at 0.5 h (A) and 3 h (B) after administration of 68Ga-DOTA-NAPamide in a melanoma-bearing mouse. Tracer uptake is seen predominantly in tumor and bladder.

 


View larger version (42K):

[in a new window]
  		FIGURE 4. Coronal PET images of AR42J-tumor bearing mice at 90 min after administration of 0.5 MBq 68Ga-BZH3. Tracer uptake in tumors, pancreas, and duodenum.

 


View larger version (67K):

[in a new window]
  		FIGURE 5. Fusion image of MR scan and 68Ga-DOTATOC PET in patient with meningioma. PET scan was acquired 1 h after tracer administration.

 


View larger version (30K):

[in a new window]
  		FIGURE 6. 18F-FDG PET (320 MBq injected dose) (A) and 68Ga-DOTATOC PET (169 MBq) (B) images obtained at 60 min after tracer administration in patient with abdominal carcinoid. 68Ga-DOTATOC scan showed higher accumulation of tracer in tumor (SUV in primary tumor [PT] = 38) than did 18F-FDG (SUV = 1.6). Four lymph node (LN) metastases are shown with 68Ga that were missed with 18F-FDG. PT and LN metastases were proven histologically. (C) Tracer kinetics for 68Ga-DOTATOC in primary tumor and bowel.

 


View larger version (57K):

[in a new window]
  		FIGURE 7. 18F-FDG PET (350 MBq injected dose) (A) and 68Ga-DOTATOC PET (250 MBq injected dose) (B) images obtained at 60 min after tracer administration in a patient with a small cell lung carcinoma. 18F-FDG shows higher accumulation (SUV = 10.6) than 68Ga-DOTATOC (SUV = 6.0).

 


View larger version (109K):

[in a new window]
  		FIGURE 8. 68Ga-labeled bombesin analog image showing primary prostate carcinoma (PCA) and a pelvic metastasis (region of interest [ROI] 2:ROI 1 = 1:202).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.